{"article_title": "Life Sciences Cases To Watch In 2016", "article_keywords": ["life", "tracking", "attorneys", "watch", "sciences", "york", "split", "sets", "cases", "2016", "view"], "article_url": "http://www.law360.com/articles/737239/life-sciences-cases-to-watch-in-2016", "article_text": "Life Sciences Cases To Watch In 2016\n\nLaw360, New York (December 24, 2015, 8:37 PM ET) -- Attorneys in the life sciences industry will be tracking cases on issues such as the approval path for biosimilar drugs and a circuit split on product-hopping in the coming year, making for a very busy 2016.\n\n\n\nHere are six sets of life sciences cases that attorneys should be keeping their eye on in 2016.\n\n\n\nBiosimilars Ruling Aftermath\n\n\n\nBiosimilars litigation is \u201cgoing to explode\u201d in 2016, Irell & Manella LLP partner David Gindler said. At least four major cases are pending involving the Affordable Care Act's biosimilar...\n\nTo view the full article, register now.", "article_metadata": {"description": "Attorneys in the life sciences industry will be tracking cases on issues such as the approval path for biosimilar drugs and a circuit split on product-hopping in 2016. Here are six sets of life sciences cases that attorneys should be keeping their eye on.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/737239/life-sciences-cases-to-watch-in-2016", "csrf-token": "q/sDcs1bhqMuGQzEHkjUm95vLUdZzeTTcLPETYZjBDkgJW+fT/ZH9+t3qwXTq9y93cV4nNnKa6c35Hbs6HG1Cg==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/737239/life-sciences-cases-to-watch-in-2016", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Life Sciences Cases To Watch In 2016 - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "Here are six sets of life sciences cases that attorneys should be keeping their eye on in 2016.\nLife Sciences Cases To Watch In 2016Law360, New York (December 24, 2015, 8:37 PM ET) -- Attorneys in the life sciences industry will be tracking cases on issues such as the approval path for biosimilar drugs and a circuit split on product-hopping in the coming year, making for a very busy 2016.\nAt least four major cases are pending involving the Affordable Care Act's biosimilar...To view the full article, register now.\nBiosimilars Ruling AftermathBiosimilars litigation is \u201cgoing to explode\u201d in 2016, Irell & Manella LLP partner David Gindler said."}